Attendance an online digital event on Sep. 24, 2024 entitled “Artificial Intelligence for the Design of New RNA Nanocarriers”. The event was offered by International Pharmaceutical Federation (FIP).

Description: To meet the demand for efficient RNA transport beyond the liver, the lab develops biocompatible, inhalable nanocarriers for siRNA delivery to the lung. While siRNA medications mainly target the liver, the lung offers undruggable sites for RNA treatments. Nebulizable nanocarriers for pulmonary RNA delivery may offer transport beyond the liver. To protect RNA and support membrane transport, siRNA therapies are delivered as GalNac conjugates or encapsulated in lipid nanoparticles (LNPs). However, approved LNPs hold immunogenic hazards, mainly target the liver, and possess a modest drug load. In addition, lipid-based carriers are unstable in lung surfactants and during nebulization stress. To address these challenges, the researchers developed polymer-based siRNA formulations.

Moderator:

- Mathew Cherian, Consultant, USA.

Co-moderator:

- Nikolina Biskic, Regulatory Affairs Manager, Switzerland.

Panellists:

- Olivia Merkel, Professor of Drug Delivery Ludwig Maxmillian University (LMU), Munich, Germany.